Literature DB >> 8069578

Evaluation of the bile acid transporter in enhancing intestinal permeability to renin-inhibitory peptides.

D C Kim1, A W Harrison, M J Ruwart, K F Wilkinson, J F Fisher, I J Hidalgo, R T Borchardt.   

Abstract

To evaluate the bile acid transporter as a means of enhancing the ability of renin-inhibitory peptides (RIPs) to penetrate the intestinal mucosa, two RIP-cholic acid conjugates and an RIP-taurocholic acid conjugate were synthesized. Conjugation was through the N-terminus of an RIP and the 3-position of the bile acid, via a six-carbon spacer. An RIP derivative containing the spacer without the bile acid moiety was also synthesized. The bile acid-RIP conjugates and the RIP derivative were shown to be potent inhibitors of human renin in vivo and to have in vivo hypotensive activity equivalent to that of the parent RIP (ditekiren) in a human renin-infused rat model. The ability of these RIP derivatives to bind to the bile acid transporter and be transported across an epithelial cell monolayer was evaluated in an in vitro model of the intestinal mucosa consisting of Caco-2 cell monolayers grown on microporous membranes. One of the RIP-cholic acid conjugate (KI = 60 +/- 10 microM) and the RIP-taurocholic acid conjugate (KI = 19 +/- 5 microM), but not the RIP derivative, were shown to be potent inhibitors of the apical (AP) to basolateral (BL) transport of [14C]-taurocholic acid ([14C]-TA). At concentrations up to 250 microM these RIP-bile acid conjugates had no effect on the diffusion of [3H]-PEG (800-1000), which is a marker of the paracellular pathway. The permeability coefficients of the RIP-bile acid conjugates, determined using Caco-2 cell monolayers, were shown to be six times less than that of [3H]-PEG (800-1000). In addition, the transport of one of the RIP-cholic acid conjugates was investigated in perfused rat ileum in which the mesenteric vein was cannulated. The conjugate was not detected in blood samples taken from the mesenteric vein, while its concentration in intestinal perfusate remained almost constant during the perfusion experiment. These results suggest that while the peptide-bile acid conjugates retain binding affinity for the intestinal bile acid transporter, the molecules are not themselves transported.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8069578     DOI: 10.3109/10611869308996094

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  4 in total

1.  Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity.

Authors:  M Kågedahl; P W Swaan; C T Redemann; M Tang; C S Craik; F C Szoka; S Oie
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 2.  Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.

Authors:  Anand Balakrishnan; James E Polli
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

3.  Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.

Authors:  Fuxing Tang; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 4.  Exploitation of bile acid transport systems in prodrug design.

Authors:  Elina Sievänen
Journal:  Molecules       Date:  2007-08-16       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.